Frequently Asked Questions: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders

Document first published:
Page updated:
Topic:
,
Publication type:

This document should be read alongside the operational note of 7 April, the JCVI advice and the MHRA advice.

Link

Frequently Asked Questions: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders

Frequently Asked Questions: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders

NHS England is not responsible for content on external websites.

Summary

Published 15 April 2021.

Document

Frequently Asked Questions: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders

Frequently Asked Questions: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders

  • PDF
  • 113 KB
  • 3 pages

Summary

Published 15 April 2021.